Literature DB >> 19342474

Immunotherapeutics in development for prostate cancer.

Andrea L Harzstark1, Eric J Small.   

Abstract

Whereas chemotherapy is the standard of care for metastatic castration-resistant prostate cancer and is associated with a survival benefit, there remains a need for alternative approaches. Extensive work has been done evaluating multiple immunotherapies for the treatment of prostate cancer. This review discusses clinical results for the most promising developments. These include cytokine-based therapy with GM-CSF; vaccines; antibody-based immunotherapies, including anti-cytotoxic T lymphocyte associated antigen 4 therapy and antibodies against additional targets; and dendritic cell-based immunotherapy.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19342474     DOI： 10.1634/theoncologist.2008-0240

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


  12 in total

Review 1.  Cancer immunotherapy: a paradigm shift for prostate cancer treatment.

Authors:  Dev Karan; Jeffrey M Holzbeierlein; Peter Van Veldhuizen; J Brantley Thrasher
Journal:  Nat Rev Urol       Date:  2012-05-29       Impact factor: 14.432

Review 2.  [Systemic treatment of metastatic prostate cancer].

Authors:  B Wörmann; J M Wolff
Journal:  Urologe A       Date:  2010-02       Impact factor: 0.639

3.  Castration-resistant prostate cancer: new science and therapeutic prospects.

Authors:  Joaquim Bellmunt; William K Oh
Journal:  Ther Adv Med Oncol       Date:  2010-05       Impact factor: 8.168

4.  Oncolytic virus-initiated protective immunity against prostate cancer.

Authors:  Shashi A Gujar; D A Pan; Paola Marcato; Katy A Garant; Patrick W K Lee
Journal:  Mol Ther       Date:  2011-01-18       Impact factor: 11.454

5.  Predicting outcomes of prostate cancer immunotherapy by personalized mathematical models.

Authors:  Natalie Kronik; Yuri Kogan; Moran Elishmereni; Karin Halevi-Tobias; Stanimir Vuk-Pavlović; Zvia Agur
Journal:  PLoS One       Date:  2010-12-08       Impact factor: 3.240

Review 6.  Novel targeted therapeutics for metastatic castration-resistant prostate cancer.

Authors:  Emmanuel S Antonarakis; Michael A Carducci; Mario A Eisenberger
Journal:  Cancer Lett       Date:  2009-08-29       Impact factor: 8.679

7.  Defining the critical hurdles in cancer immunotherapy.

Authors:  Bernard A Fox; Dolores J Schendel; Lisa H Butterfield; Steinar Aamdal; James P Allison; Paolo Antonio Ascierto; Michael B Atkins; Jirina Bartunkova; Lothar Bergmann; Neil Berinstein; Cristina C Bonorino; Ernest Borden; Jonathan L Bramson; Cedrik M Britten; Xuetao Cao; William E Carson; Alfred E Chang; Dainius Characiejus; A Raja Choudhury; George Coukos; Tanja de Gruijl; Robert O Dillman; Harry Dolstra; Glenn Dranoff; Lindy G Durrant; James H Finke; Jerome Galon; Jared A Gollob; Cécile Gouttefangeas; Fabio Grizzi; Michele Guida; Leif Håkansson; Kristen Hege; Ronald B Herberman; F Stephen Hodi; Axel Hoos; Christoph Huber; Patrick Hwu; Kohzoh Imai; Elizabeth M Jaffee; Sylvia Janetzki; Carl H June; Pawel Kalinski; Howard L Kaufman; Koji Kawakami; Yutaka Kawakami; Ulrich Keilholtz; Samir N Khleif; Rolf Kiessling; Beatrix Kotlan; Guido Kroemer; Rejean Lapointe; Hyam I Levitsky; Michael T Lotze; Cristina Maccalli; Michele Maio; Jens-Peter Marschner; Michael J Mastrangelo; Giuseppe Masucci; Ignacio Melero; Cornelius Melief; William J Murphy; Brad Nelson; Andrea Nicolini; Michael I Nishimura; Kunle Odunsi; Pamela S Ohashi; Jill O'Donnell-Tormey; Lloyd J Old; Christian Ottensmeier; Michael Papamichail; Giorgio Parmiani; Graham Pawelec; Enrico Proietti; Shukui Qin; Robert Rees; Antoni Ribas; Ruggero Ridolfi; Gerd Ritter; Licia Rivoltini; Pedro J Romero; Mohamed L Salem; Rik J Scheper; Barbara Seliger; Padmanee Sharma; Hiroshi Shiku; Harpreet Singh-Jasuja; Wenru Song; Per Thor Straten; Hideaki Tahara; Zhigang Tian; Sjoerd H van Der Burg; Paul von Hoegen; Ena Wang; Marij Jp Welters; Hauke Winter; Tara Withington; Jedd D Wolchok; Weihua Xiao; Laurence Zitvogel; Heinz Zwierzina; Francesco M Marincola; Thomas F Gajewski; Jon M Wigginton; Mary L Disis
Journal:  J Transl Med       Date:  2011-12-14       Impact factor: 5.531

8.  The immuno-regulatory effects of Schisandra chinensis and its constituents on human monocytic leukemia cells.

Authors:  Rong-Dih Lin; Yi-Wen Mao; Sy-Jye Leu; Ching-Yi Huang; Mei-Hsien Lee
Journal:  Molecules       Date:  2011-06-10       Impact factor: 4.411

9.  Pharmacokinetics of combined gene therapy expressing constitutive human GM-CSF and hyperthermia-regulated human IL-12.

Authors:  Fang Wei; Huiping Wang; Jufeng Zhang; Xiafang Chen; Chuanyuan Li; Qian Huang
Journal:  J Exp Clin Cancer Res       Date:  2013-01-26

10.  Prostate Cancer Immunotherapy: Exploiting the HLA Class II Pathway in Vaccine Design.

Authors:  Bently P Doonan; Azizul Haque
Journal:  J Clin Cell Immunol       Date:  2015-08-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.